Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
TEL AVIV, Israel, July 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd.
(TASE: EMIT, Nasdaq: EMITF ), announced today that, its subsidiary (in which
EI holds indirectly approximately 58.34%, InSightec Ltd., announced today
that a team at the University Children's Hospital Zurich has completed...
FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen(R) (decitabine for ...
Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ -- Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the worl...
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...
CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
VIENNA, Va., June 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM ) announced today that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A...
Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
Phase 1/2 Calcium Upregulation by Percutaneous Administration (CUPID) Data Highlight Safety Profile and Biological Effects of SERCA2a Enzyme Replacement
SAN DIEGO, May 26 /PRNewswire/ -- Celladon Corporation today announced that results from its genetically targeted enzyme replacement therapy...
Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
NATICK, Mass., May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disea...
Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
DURHAM, N.C., May 13 /PRNewswire/ -- Addrenex Pharmaceuticals today expanded its pipeline of products aimed at adrenergic regulation with the signing of an agreement to license a new drug for the treatment of narcolepsy, a chronic and debilitating sleep disorder, as well as other neurologic and ps...
Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
DENVER, April 21 /PRNewswire-USNewswire/ -- Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented data today at the American Association for Cancer Research's 100th Annual Meeting 2009 that could potentially provide a brighter future for children who su...
New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
DENVER, April 1 /PRNewswire-USNewswire/ -- Responding to President Obama's call for "a cure for cancer in our time," the Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline for cancer. The report shows that America's pharm...
Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
-Company Provides Update on Cash Position-
-Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks-
EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE ) announced today positive top-line efficacy results ...
Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease
LOS ANGELES, Feb. 16 /PRNewswire/ -- Scientists announced today the
publication of a landmark peer-reviewed paper in the February issue of the
Bentham Open Stem Cell Journal which outlines the long term results of the
world's first clinical trial using autologous neural stem cells for the
Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
HOLLYWOOD, Fla., Jan. 19 /PRNewswire/ -- Stents can be placed in the brain to treat
a stroke as it's occurring, suggests preliminary data being presented at the 21st Annual International Symposium on Endovascular Therapy (ISET).
Stents have long been used to open up blocked blood vessels in t...
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals,
Inc. (Nasdaq: JAZZ ) today announced completion of enrollment in the second of
two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the
treatment of fibromyalgia.
"Completion of enrollment in thi...
Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease
Research Uncovers New Link Between Inflammation & Alzheimer's Disease
SARASOTA, Fla., Dec. 16 /PRNewswire/ -- The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer's disease and have identified a potential target for de...
Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
MIAMI, Nov. 12 /PRNewswire/ -- The Miami Jewish Home and Hospital,
Berma Research Group, and Segal Institute for Clinical Research today
announced that they are actively enrolling patients in the CONNECTION
study, a Phase 3 clinical trial that is evaluating the safety and efficacy
of the inves...
Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH)
-- Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease
-- Imatinib mesylate, available as Gleevec(R)...
Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
AUSTIN, Texas, Oct. 7 /PRNewswire/ -- The Texas Cardiac Arrhythmia
Institute (TCAI) at St. David's Medical Center has been selected as one of
only a few sites in the nation to participate in an FDA-approved clinical
trial for a new device to treat
persistent atrial fibrillation. TCAI, an
Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera
SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Napo Pharmaceuticals (LSE:
NAPL/NAPU) today announces positive clinical data on the effectiveness of
crofelemer from a study for CRO-ID in treating severely ill cholera
patients in conjunction with an antibiotic and rehydration therapy.
A double-blind ...
Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
PALO ALTO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Jazz
Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced that the final patient
has completed participation in the first Phase III pivotal clinical trial
of JZP-6 (sodium oxybate) for the treatment of fibromyalgia.
The JZP-6 Phase III ...
Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
Non-stimulant drug addresses wide range of symptoms of ADHD
DURHAM, N.C., Sept. 10 /PRNewswire/ -- A drug that diminishes the
body's hyper-reactivity to stress has been shown to significantly reduce
symptoms of attention-deficit hyperactivity disorder (ADHD) in children,
according to a p...
New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
Results add to body of clinical evidence demonstrating the efficacy and safety of synthetic mesh slings for treatment of stress urinary incontinence in women.
SOMERVILLE, N.J., Sept. 8 /PRNewswire/ -- A new study published in the
August issue of International Urogyne...
Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
MONTREAL, Aug. 20 /PRNewswire/ -- Enobia Pharma, an emerging biotech
company focused on developing novel therapeutics for serious bone
disorders, today announced that the first patient in its clinical program
for hypophosphatasia has been dosed. Enobia is investigating Enzyme
Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
SEATTLE and ATLANTA, July 30 /PRNewswire/ -- A patient with pancreatic
cancer recently became the first person in the United States to receive
treatment using Elekta VMAT (Volumetric intensity Modulated Arc Therapy) at
Seattle's Swedish Cancer Institute. This revolutionary new technology
Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease
- Data from Pivotal Study Highlighted at Recent Arizona Alzheimer's Consortium Annual Conference in Phoenix -
PHOENIX and SUN CITY, Ariz., June 9 /PRNewswire/ -- Banner Alzheimer's
Institute and Sun Health Research Institute today announced that they are
actively enrolling pati...
Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
NEW ORLEANS, June 2 /PRNewswire/ -- Dr. Charles Kerber, University of
California San Diego, reported today at the American Society of
Neuroradiology Conference in New Orleans the early results on the use of a
new technology, Neucrylate(TM), to treat
cerebral aneurysms. Neucrylate is
a liquid e...
Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
PALO ALTO, Calif., June 2 /PRNewswire-FirstCall/ -- Jazz
Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced completion of
enrollment in the first of two Phase III pivotal clinical trials of JZP-6
(sodium oxybate) for the treatment of fibromyalgia.
"Completion of enrollment in this trial ...
Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
Blood pressure reductions demonstrated in Blacks, Hispanics/Latinos, People with Diabetes and Obese Individuals
PARSIPPANY, N.J., May 15 /PRNewswire/ -- Daiichi Sankyo, Inc.,
announced today that data presented at the American Society of
Hypertension's Twenty- Third Annual Scien...
Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Strativa
Pharmaceuticals, the proprietary products division of Par Pharmaceutical
Companies, Inc. (NYSE: PRX ) today announced that its development partner,
BioAlliance Pharma reported preliminary, top-line results for a Phase III
Texas Heart(R) Institute at St. Luke's Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
HOUSTON, April 14 /PRNewswire-USNewswire/ -- Physician scientists at
the Texas Heart Institute (THI) at St. Luke's Episcopal Hospital announced
they have begun the world's first clinical trial to treat
patients with a special type of stem cell to promote better healing and to
Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
- Emerging Data Shows Encouraging Response in CF Patients - Results Validate Investment in Venture Philanthropy Business Model
BETHESDA, Md., March 27 /PRNewswire/ -- The Cystic Fibrosis Foundation
announced today that VX-770, an oral drug in development that targets a
basic defect in ...
Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
BRIDGEWATER, N.J., March 11 /PRNewswire/ -- The totality of scientific
data submitted in recent months to the U.S. Food and Drug Administration
(FDA) in preparation for the March 13th Oncologic Drugs Advisory Committee
Meeting (ODAC) reaffirms that erythropoiesis-stimulating agents (ESAs) are
Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
OSAKA, Japan and PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ --
Takeda Pharmaceutical Company Limited (TSE: 4502) and Affymax, Inc.
(Nasdaq: AFFY ) today announced that Takeda has dosed the first patient in
the United States in a clinical trial of the investigational new drug,
Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
NATICK, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced CE Mark approval for its COGNIS(TM)
cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM)
implantable cardioverter defibrillator (ICD). These devices represent
Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
BRIDGEWATER, N.J. and CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ --
Results from a Phase III clinical trial evaluating the efficacy and safety
of risedronate 150 mg once monthly for the treatment of postmenopausal
osteoporosis were published this month in the January issue of the peer-
Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
BOTHELL, Wash., Jan. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK ) announced the completion of enrollment for its
Phase 2 clinical trial of PYY3-36 Nasal Spray to treat
obesity. The Company
enrolled 551 obese patients at multiple clinical sites in the United ...
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Novel non-estrogen oral therapy in development for menopausal symptoms
ANN ARBOR, Mich., Jan. 3 /PRNewswire/ -- QuatRx Pharmaceuticals Company
today announced positive results from a pivotal Phase 3 study of Ophena(TM)
(ospemifene) to treat
postmenopausal women with vulvovaginal atrophy, a
Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
MARIETTA, Ga., Dec. 12 /PRNewswire/ -- Solvay Pharmaceuticals, Inc.,
announced today that the company will continue to work closely with the
U.S. Food and Drug Administration (FDA) to fully address the questions
raised by members of the Cardio-Renal Advisory Committee in its meeting to
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Unique monoclonal antibody successfully targets human leukemic stem cells
ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading
biopharmaceutical company, has today presented data at the American Society
of Hematology (ASH) 49th annual meeting, which demonstrate the promising
Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK ) announced today the start of a Phase 2 clinical
trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The
study will enroll approximately 500 obese patients for a six-month,